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Abstract: A compound herbal formulation (POL4) is used traditionally in interior parts (Distt. Badin) of Sindh, Pakistan,
for the treatment of metabolic disorders like diabetes and hyperlipidemia. This study is aimed to determine the
effectiveness of POL4 and its ingredients in hyperlipidemia and associated endothelial dysfunction and hypertension.
POL4 is composed of equal proportion of Nigella sativa, Cichorium intybus, Trigonella foenum graecum and Gymnema
sylvestre mixed in powdered form. Chronic (6 to 7 weeks) administration of POL4 and its ingredients mixed in diet
caused a notable attenuation in total cholesterol, low density lipoprotein cholesterol, triglycerides, atherogenic index, Creactive protein and glucose, while it has increased high density lipoprotein levels. POL4 intervention markedly (p<0.01)
reduced systolic blood pressure in rats to 127±1.92 vs. 145.4±1.07 mm of Hg using tail-cuff method and significantly
(p<0.05) improved endothelium-dependent relaxation (75±2.88 vs. 82.75±1.22%) to acetylcholine in isolated aortae of
rats in treatment groups using force transducer and PowerLab system. Similar activities were assessed on the part of
ingredients of POL4. These findings indicate that POL4 and its ingredients possess antihyperlipidemic, endotheliumdependent modulatory and antihypertensive activities, thus providing an evidence to the vernacular use of POL4 in
hyperlipidemia and hypertension.
Keywords: Poly herbal formulation, antihyperlipidemic, antihypertensive, endothelial modulatory.

INTRODUCTION
Persistent hyperlipidemia is a major contributing factor
precipitating cardiovascular disorders (CVDs) such as,
hypertension, myocardial infarction, peripheral artery and
coronary artery diseases (Orsó et al., 2009).
Hyperlipidemia expedites the process of atherosclerosis
and its consequences of developing multi-vessels disease,
heart failure and stroke. Controlled lipid levels achieved
by non-pharmacological or pharmacological interventions
are known to protect from cardiovascular events
(Scicchitano et al., 2014). It is well documented that prehyperlipidemia is highly prevalent in developing (around
80%) countries including Pakistan compared to the
developed countries (Dodani et al., 2008), which might be
associated with sedentary life style and unhealthy dietary
habits. The available treatment options for hyperlipidemia
include statins, fibrates, bile acid sequestrants and niacin,
however, their prolonged use is associated with multiple
adverse effects like rhabdomyolysis, cardiomyopathy,
myopathy, osteoporosis, constipation, intolerance and
poor compliance (Last et al., 2011; Casula et al., 2012).
In Asian countries including Pakistan, the alternative
approaches, especially the use of herbal remedies and

supplements are becoming very popular nowadays for
their medical uses (Kajal et al., 2016).Herbal remedies
have gained maximum attention in current era because of
the presence of millions of constituents offering diverse
range of activities with inbuilt potential to nullify
associated adverse effects (Salvamani et al., 2014). One
of the oldest traditional systems of the world, GreecoArab/Tibb-e-Unani medicine is commonly practiced in
South Asian countries. In our settings due to cultural
acceptance, people prefer using medicinal plants or herbal
formulations for various chronic ailments like
constipation and diarrhea (Mehmood et al., 2015),
hypercholesterolemia (Naz et al., 2016), hypertension and
vascular resistance (Aziz et al., 2013; 2009). Similarly,
formulations like a combination of S. reticulate, C.
zeylanicum, L. speciosa, C. sinensis and G. sylvester for
diabetes (Baig et al., 2014), Angiosifa(Parasuraman et al.,
2013) and Itrifal Saghir (Kamali et al., 2012) are popular
for their therapeutic use as antihyperlipidemic and antiobesity, respectively. A compound herbal formulation
(POL4) is popular in our system of traditional medicine
for its medicinal utility in cardiometabolicdisorders (table
1), however no report is available in the literature to
rationalize its medicinal uses in hyperlipidemia and
hypertension.
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This study is aimed to validate the medicinal use of the
parent formulation and its ingredients in hyperlipidemia,
endothelial dysfunction and hypertension using high fat
diet-induced hyperlipidemic rat model.

to 7 days before starting the experiment. The
experimental protocol were approved from institutional
ethics committee at University of Sargodha, Sargodha,
Pakistan.

MATERIALS AND METHODS

Chemicals
Cholesterol, cholic acid, atorvastatin, acetylcholine and
phenylephrine were sourced from Sigma Chemicals, St.
Louis, MO, USA. Isoflurane was obtained from the
Pharmacy of Aga Khan University Hospital, Karachi,
Pakistan. Butterfat was procured from United King
Bakers, Bahadurabad, Karachi, Pakistan. The reagents for
the assessment of serum total cholesterol, low-density
lipoprotein
cholesterol,
high-density
lipoproteincholesterol, triglycerides, glucose and C-reactive protein
levels were purchased from Roche Diagnostic Karachi,
Pakistan, while their estimation was carried out using
Cobas c111 autoanalyzer diagnostic system (Roche
Diagnostics International Ltd., Switzerland).

Identification and preparation of polyherbal (POL4)
formulation
The ingredients [N. sativa (Ns), C. intybus (Ci), T. foenum
graecum (Tfg) and G. sylvestre (Gs)] of polyherbal
(POL4) formulation were procured from Rehmania Pinsar
Store, Sargodha and samples were identified by Dr.
Muhammad Amin Ullah Shah, Taxonomist, Department
of Botany, University of Sargodha, Sargodha, Pakistan.
The individual samples were deposited in the faculty
herbarium with following voucher numbers; N. sativa
(Malik-632), C. intybus (Malik-633), T. foenum graecum
(Malik-634) and G. sylvestre (Malik-635). All the
ingredients were powdered and mixed in equal parts to
compose POL4. For further studies, the parent formulation
and its ingredients were mixed in the diet of different
HFD-fed animal groups.
Animals
Sprague-Dawley rats (180-250g) of either sex, kept at the
“Animal House” of Aga Khan University, Karachi, were
used in this study. The animals were maintained at
moderate temperature (23±5°C), acceptable relative
humidity (55±5%), 12-hr light/dark periods and were kept
in plastic cages containing sawdust (changed after two
days). Animals were given normal diet and tap water. All
the animals were grouped at random in desired number of
groups by numbering method and were acclimatized for 5

Preparation of different diets and intervention
Different diets were used in this study. Normal diet (ND)
was developed at the animal house of Aga Khan
University. ND consists of (gram/kilogram): fiber 380,
flour 380, molasses 12, powdered milk 150, sodium
chloride 5.8, vegetable oil 38, potassium metabisulphate
1.2, nutrivet-L 2.5, fish meal 170. A total of 56 rats were
randomly divided into 8 groups. Animals in group 1 (n=7)
were administered the normal diet. High fat diet (HFD)
was prepared using combination of cholesterol, cholic
acid and butter fat (2, 0.5 and 5% w/w), respectively, an
addition to normal diet components for 6-7 weeks (Aziz
et al., 2013).Animals in groups 2-8 (n=7 in each group)
were administered HFD. The animals in groups 4-8 were

Table 1: Showing description of the ingredients of compound herbal formulation
Ingredients of
POL4(Botanicals)
Nigella sativa, L.

Vernacular
names/part used
Black seed,
Kalonji /seeds

Cichorium
intybus, L.

Chicory, Kasni /
seeds

Asteraceae

Trigonella
foenum
graecum, L.

Fenugreek,
Methi /seeds

Fabaceae

Gymnema
sylvestre, R.Br.

Gurmar booti /
leaves

Asclepiadaceae
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Family
Ranunculaceae

Medicinal uses
Hypocholesterolemic,
hypoglycemic,
cardiodepressant(Razavi and
Hosseinzadeh, 2014)
Hypocholesterolemic,
hypoglycemic,
cardiodepressant, cardiotonic
(Nadkarni, 1986; Street et al.,
2013).
Hypocholesterolemic,
antidiabetic,
hypotriglyceridemic (Duke et
al., 2002; Chaturvedi et al.,
2013).
Hypocholesterolemic,
cardiotonic, hypoglycemic,
antiobesity (Nadkarni, 1986;
Tiwari et al., 2014).

Phytochemical
Constituents
Flavonoids, saponins,
thymoquinone and
tocopherols (Khan and
Afzal, 2016)
Tannins, flavonoids,
saponins and
caffeoylquinic acid
(Street et al., 2013)
Flavonoids, diosgenin,
trigonelline and 4hydroxyisoleucine
(Khorshidian et al., 2016)
Flavonoids, saponins,
tannins, gymnemic acid
and deacylgemnemic acid
(Tiwari et al., 2014)
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administered POL4 and its ingredients mixed in diet at a
dose of 6% w/w, respectively. The animals in group 3
were administered atorvastatin (a standard lipid lowering
drug), at 10mg/kg/day dissolved in distilled water and
given through oral gavage (Belagali et al., 2013). All
measures were ensured for uniform mixing of POL4 and
its ingredients with normal diet.
Assessment ofnon-invasive blood pressure in nonanaesthetized rats
Non-invasive blood pressure was recorded at day 0 and at
week 6 and/or 7 of the study using
tail cuff
plethysmography (Model 92, IITC Inc., Woodland Hills,
USA) joined with PowerLab (4/25) data attainment
system linked to a computer with installed software of
Chart 5.3 (AD Instruments, Sydney, Australia). Prior to
the study protocol, the animals were given training skills
for easy blood pressure measurement. As soon as the
animals got acclimatized for these procedures, 4–6
measurements, within time interval of 4-8 min, of systolic
blood pressure in non-anaesthetized rats were attained and
the mean values were calculated accordingly. Possible
experimental variables like body temperature at 27°C,
respiration, body motion and noise intensity were made
minimum to get quality results (Aziz et al., 2009).
Measurement of endothelium-dependent vasorelaxation
in rat aortic preparations
At terminal day of the experimental protocol, rats fasted
for 12-16 hr were euthanized followed by anesthesia with
isoflurane (2-5% v/w) by inhalation in a closed chamber
until achievement of deep anesthesia. Dissection was
performed at earliest to remove thoracic aortae. All the
aortae were shifted to Kreb's solution with ingredients in
mmol/L: [NaCl (118.4), KCl (4.7), KH2PO4 (1.2), MgSO4
(1.20, NaHCO3 (25), glucose (11) and CaCl2 (2.5) with
pH 7.4], cleaned of attached fatty tissues and were sliced
into rings of 2 to 3 mm length. Afterward aortic rings
were immersed in tissue bath assembly loading Kreb's
solution at 37°C, bubbled with carbogen (95% O2 and 5%
CO2), connected with a force transducer (50-7905,
Harvard Apparatus, USA) and PowerLab data recording
system (Model ML845, AD Instruments, Australia). The
aortic rings were stabilized for 45 min at normal tension
of 2g, with refreshing physiological salt solution at every
15 min. After stabilization, acetylcholine concentration
response curves (ACh; 1×10−8 to 10−4mol/L) were
constructed on phenylephrine (P.E; 1×10−6mol/L)-induced
contractions (Amin et al., 2015).
Biochemical estimations
Estimation of lipid profile, glucose and CRP
The rats were exposed to isoflurane (2-5% v/w by
inhalation) in a closed chamber until fully anesthetized.
The blood samples were withdrawn in vacutainer by
cardiac puncture from overnight fasted rats. The blood
samples were centrifuged at 3000 rpm for 10min
Pak. J. Pharm. Sci., Vol.30, No.1(Suppl), January 2017, pp.295-301

(Beckman Coulter Allegra X-22, USA) to extract serum.
The estimation of serum total cholesterol (TC), lowdensity lipoprotein-cholesterol, high-density lipoproteincholesterol (HDL-C), triglycerides, glucose and Creactive proteins was carried out using Cobas c111 auto
analyzer. Body weights were also measured for the
determination of weight variations. Atherogenic index
(AI) and coronary risk index (CRI) were calculated using
formula: AI= TC-HDL-C/HDL-C and CRI= TC/HDL-C.

STATISTICAL ANALYSIS
The data was presented as means ± S.E.M. Student's t-test
was applied for comparison between two groups, , while
One-way ANOVA (analysis of variance) was applied to
compare means in multiple groups by Dunnett's and/or
Tukey’s post-test. P value of less than 0.05 was accounted
significantly different. All graphs were constructed using
GraphPad Prism software (GraphPad Software,
California, USA).

RESULTS
Effects of treatment on serum parameters in high fat
diet-induced hyperlipidemic rats
Chronic administration of high fat diet (HFD) caused a
significantly increase in serum total cholesterol (TC), low
density lipoprotein-cholesterol (LDL-C), triglycerides
(TG), C-reactive proteins (CRP), atherogenic index (AI)
and coronary risk index (CRI), while it has decreased the
high density lipoprotein-cholesterol (HDL-C) compared
to normal diet control. Administration of POL4 and its
ingredients to HFD-fed rats at a dose of 6% w/w reversed
the raised parameters including TC, LDL-C, TG, AI, CRI
and CRP, while this intervention has also cause a
significantly rise in HDL-C levels compared to HFD-fed
rats without any treatment. Similar effects have been
observed on the part of positive control of atorvastatin (10
mg/kg/day, oral gavage), a standard lipid lowering agent.
The body weight was decreased due to slight reduction in
daily feed intake in treatment groups compared to control.
The comparative effect of different groups on selected
serum parameters has been presented in table 2.
Effect of different treatments on systolic blood pressure
The chronic administration of POL4 and its ingredients to
high fat diet (HFD)-fed rats significantly reduced systolic
blood pressure to 127±1.92 vs. 145.4±1.07mm of Hg
(mean ± SEM; n=6–7). The comparative systolic blood
pressure lowering effect in different groups has been
presented in fig. 1.
Effect of treatment on endothelium-dependent reactivity
Administration of POL4 and its ingredients to HFD-fed
rats caused significant improvement in endotheliumdependent relaxation by augmenting acetylcholine (ACh)mediated relaxation to 75.0±2.88 vs. 82.75±1.22% (n=6–
7). The HFD administration to rats resulted in

297

Studies on antihyperlipidemic and endothelium modulatory activities
Table 2: Effect of different treatments on serum parameters of HFD-fed rats
Parameters
TC (mg/dL)
LDL-C (mg/dL)
HDL-C (mg/dL)
TG (mg/dL)
AI
CRI
Glucose mg/dL)
CRP (mg/L)
Weight variation
(%age)

ND

HFD

73.5 ±
7.75
38.7 ±
4.66
33.2 ±
1.32
64.7 ±
4.95
1.35 ±
0.17
2.3 ± 0.36
109.7 ±
5.62
0.026 ±
0.016
32.2 ±
1.98

317.2 ±
###
11.82
267.6 ±
8.47###
20.2 ±
###
1.45
83.5 ±
5.56###
14.66 ±
3.35###
15.7 ±
###
2.02
119.4 ±
4.17##
0.153 ±
0.83###
47.8 ±
2.22###

HFD +
Atorva

HFD +
POL4

143.8 ±
5.29***
97.8 ±
5.25***
25.2 ±
1.26ns
75.2 ±
1.25*
4.72 ±
1.40**
5.6 ±
1.14***
112.2 ±
2.12ns
0.147±
0.027ns
40.2 ±
1.05*

169.2 ±
15.47***
121.2 ±
10.05***
28.4 ±
3.65**
74.8 ±
3.76**
4.94 ±
1.29**
5.7 ±
0.95***
81.2 ±
4.64***
0.144 ±
0.034*
37.2 ±
1.56**

HFD +
N. sativa
164.4 ±
11.05***
133.6 ±
9.46***
27.9 ±
2.05**
75.7 ±
3.52*
4.80 ±
0.96**
5.8 ±
1.07***
83.6 ±
5.53***
0.145 ±
0.092*
36.4 ±
2.33**

HFD +
C. intybus
156.5 ±
8.42***
105.8 ±
6.72***
26.9 ±
2.14*
76.4 ±
2.45*
5.0 ±
1.63**
6.1 ±
0.75***
86.8 ±
7.12***
0.146 ±
0.042ns
39.2 ±
1.46*

HFD +
T. foenum
graecum
175.4 ±
6.63***
145.2 ±
7.33***
27.2 ±
1.15*
74.3 ±
3.58**
5.23 ±
1.46**
6.3 ±
1.02***
73 ±
4.34***
0.144 ±
0.052*
37.7 ±
1.68**

HFD +
G.
sylvestre
177.0 ±
8.00***
164.8 ±
9.12***
26.1 ±
3.94*
75.9 ±
5.90*
6.73 ±
0.95*
5.1 ±
1.24***
62.2 ±
5.15***
0.147 ±
0.062ns
38.4 ±
2.11**

Values shown are means ± SEM, n=7, ###p<0.001 and ##p<0.01 compared to ND (unpaired student’s t-test), while ns (nonsignificant),*p<0.05, **p<0.01 and ***p<0.001 compared to HFD (One way-ANOVA followed by Tukey’s post-test).
POL4 (poly herbal formulation); Ns (N. sativa); Ci (C. intybus); Tfg (T. foenum graecum); Gs (G. sylvestre); ND (normal diet); HFD
(high fat diet); TC (total cholesterol); LDL-C (low density lipoprotein-cholesterol); HDL-C (high density lipoprotein-cholesterol);
TG (triglycerides); CRP (C-reactive protein); AI (atherogenic index) and CRI (coronary risk index).

Systolic Blood Pressure
(m m of H g)

160

***
##

##

##

##

##

#

120
80

ND
HFD
HFD + Atorva
HFD + POL4
HFD + Ns
HFD + Ci
HFD + Tfg
HFD + Gs

40
0

Treatments
Fig. 1: Effect of different treatments on systolic blood pressure in HFD-fed rats
Data represent the means ± SEM of 6 to 7 determinants. ***p<0.001 shows a comparison of ND vs. HFD (unpaired student’s t-test),
while ns (non-significant), #p<0.05 and ##p<0.01 show a comparison of treatment groups vs. HFD (one-way ANOVA followed by
Dunnett’s test). POL4 (polyherbal formulation); Ns (N. sativa); Ci (C. intybus); Tfg (T. foenum graecum); Gs (G. sylvestre); ND
(normal diet); HFD (high fat diet); Atorva (atorvastatin).

endothelium dysfunction which was evident by resistance
to ACh-mediated inhibitory response in the isolated aortic
rings as shown in fig. 2. The comparisons of ACh
concentration-response curves in the aortic preparations
of different treatment groups were presented in fig. 2.
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DISCUSSION
In view of the folkloric medicinal use of ingredients of
POL4 and the combined formulation in cardiometabolic
disorders like hyperlipidemia and hypertension(Duke et
Pak. J. Pharm. Sci., Vol.30, No.1(Suppl), January 2017, pp.295-301
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% of P.E (1 µM)-induced
Vasoconstriction

100
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#
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ND
HFD only
HFD + Atorva
HFD + POL4
HFD + Ns
HFD + Ci
HFD + Tfg
HFD + Gs
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0
-8

-7

***

-6

-5

-4

ACh Challenge [µM]
Fig. 2: Effect of different treatments on endothelium-dependent relaxation in isolated aortae of HFD-fed rats.
Data show the means ± SEM of 6 to 7 sets of experiments. ***p<0.001 shows a comparison of HFD with ND (Student’s t-test),
while ns (non-significant), #p<0.05 and ##p<0.01 show a comparison of all treatments with HFD (One way-ANOVA followed by
Tukey’s post-test). POL4 (polyherbal formulation); Ns (N. sativa); Ci (C. intybus); Tfg (T. foenum graecum); Gs (G. sylvestre); ND
(normal diet); HFD (high fat diet); Atorva (atorvastatin).

al., 2002), POL4 and its individual components [N. sativa,
C. intybus, T. foenum graecum,G. sylvestre] mixed in diet
were administered to HFD-fed rats. These interventions
prevented raised serum total cholesterol (TC), low-density
lipoprotein-cholesterol (LDL-C), triglycerides (TG), Creactive proteins (CRP), atherogenic index (AI), coronary
risk index (CRI) and fasting blood glucose. Similarly,
atorvastatin (suspended in distilled water and
administered through oral gavage) also reduced the raised
lipid profile. The treatment with POL4 and its ingredients
also significantly increased high-density lipoproteincholesterol (HDL-C) compared to only HFD-fed rats. The
body weight was compromised accompanied by a
reduction in daily feed intake in intervention groups
compared to HFD fed rats. These findings have clearly
suggested that POL4 affects cholesterol/lipoprotein
distribution and plays a part in uptake of HDL-C, thus
resulting in an up-regulation of LDL-C hepatic receptors
known to catabolize increased LDL-C(Krause et al.,
1984). This may be due to the presence of a potent
antioxidant, ascorbic acid or tocopherols in POL4 (Razavi
and Hosseinzadeh, 2014; Vanamala et al., 2012), while
presence of polyphenols, 4-hydroxyisoleucine, saponins
and soluble fibers in T. foenum graecum, known for lipid
lowering effect, may have a contributing role in observed
antihyperlipidemic effects (Chaturvedi et al., 2013; Madar
and Stark, 2002).
High fat diet containing cholesterol, cholic acid and
butterfat at 2, 0.5 and 5% w/w, respectively, is known to
alter lipid peroxidation and antioxidant enzymes resulting
Pak. J. Pharm. Sci., Vol.30, No.1(Suppl), January 2017, pp.295-301

in increased oxidative stress leading to development of
obesity, vascular dysfunction and hypertension in
experimental animals (Tobert, 2003; Olusi, 2002).
Increased body weight and/or adipocyte hypertrophy,
hepatic steatosis and visceral adiposity are the outcomes
of chronic use (Jin et al., 2013). Prolonged use of HFD
enhances serum TC, very low density lipoproteincholesterol (VLDL-C), LDL-C, AI and CRI (Mopuri and
Meriga, 2014). The cholic acid is well known to help
cholesterol and fat assimilation and also blocks the
conversion of cholesterol into bile acid, hence causing
increase in the pool of cholesterol in serum(Ando et al.,
2005). Thus, the test material(s) offering protection
against hyperlipidemia in HFD-fed animal model may be
because of its inhibitory influence on cholesterol and fat
absorption from dietary source as observed on the part of
POL4 and its ingredients.
Oxidative stress, one of the characteristic features of HFD
administration, is a major culprit in development of
hypercholesterolemia,
endothelium-dependent
dysfunction and atherosclerosis. Triggered oxidative stress
along with hypercholesterolemia has synergistic role to
accelerate the development of vascular resistance,
hypertension and associated complications like coronary
artery disease, myocardial ischemia and myocardial
infarction in animals and humans (Tobert, 2003; Lind,
2002). When assessed for effect on systolic blood
pressure (SBP) and endothelial function, the parent
formulation and its components have decreased SBP and
improved the endothelium-dependent relaxation by
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causing an increase in ACh-induced relaxation in
following orders: Ci>Tfg>POL4Ns. This study reports
first time the blood pressure lowering and endothelial
modulating properties of POL4 and C. intybus in HFD-fed
rats, however, G. sylvestre has been found relatively the
least effective as antihypertensive which is also in line
with previous studies for its antihypertensive effect in
different animal models (Preuss et al., 1998; Bhansali et
al., 2013). Similarly, the weak endothelial modulatory
activity has been observed on the part of G. sylvestre
indicating that its exclusion from current form of the
formulation may be suggested if used for the treatment of
hypertension.
Numerous studies have reported that high fat diet
significantly increases body weight by causing
accumulation of adipose tissue (Hariri and Thibault, 2010;
Reuter, 2007). The present study has demonstrated that
HFD intake induces obesity which was evident by the
significant weight gains in HFD-fed animals. The
administration of POL4 and its components to HFD-fed
rats have exhibited beneficial effects on weight gain and
food intake as compared to HFD-fed rats without any
treatment. This contribution might be because of the
existence of some of the secondary metabolites in N.
sativa like thymoquinone and tocopherols and in G.
sylvestre like gymnemic acid and deacylgemnemic acid
which are known for their antiobesity activities (HasaniRanjbar et al., 2013; Pothuraju et al., 2014; Manish et al.,
2011).

CONCLUSION
This study has shown that POL4 and its ingredients
possess antihyperlipidemic, endothelium- modulating and
antihypertensive properties. The antihyperlipidemic
property may be attributed to the inhibitory influence of
POL4 on absorption and synthesis of lipids. Thus, this
study provides an evidence to the empirical medicinal use
of POL4 and its constituents in cardiovascular disorders
like hyperlipidemia and hypertension.
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